Get the Stockscreener App
104.46
0.01%
-0.01
After Hours:
104.46
Axsome Therapeutics Inc stock is traded at $104.46, with a volume of 421.18K.
It is down -0.01% in the last 24 hours and down -16.88% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$104.47
Open:
$104.35
24h Volume:
421.18K
Relative Volume:
0.47
Market Cap:
$5.05B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-16.00
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
+9.21%
1M Performance:
-16.88%
6M Performance:
+11.90%
1Y Performance:
+49.85%
1-Day Range:
$103.98
$105.66
1-Week Range:
$93.95
$105.66
52-Week Range:
$64.11
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
104.46 | 5.05B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Kennedy Capital Management LLC Raises Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
91,649 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Granite Investment Partners LLC - MarketBeat
Invesco Ltd. Increases Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
LPL Financial LLC Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Reduced by Alliancebernstein L.P. - MarketBeat
Leerink Partnrs Analysts Cut Earnings Estimates for AXSM - MarketBeat
XTX Topco Ltd Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for AXSM Earnings - MarketBeat
Affinity Asset Advisors LLC Sells 5,000 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Geode Capital Management LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Trexquant Investment LP Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
This Little-Known Stock Could Be One of the Best Recession-Proof Investments Now - The Globe and Mail
Is Axsome Therapeutics (NASDAQ:AXSM) A Risky Investment? - simplywall.st
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law Firm - Kilgore News Herald
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO - GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT) Should Contact Grabar Law Office Today - GlobeNewswire Inc.
Zacks Research Analysts Decrease Earnings Estimates for AXSM - MarketBeat
What is Zacks Research's Forecast for AXSM FY2025 Earnings? - MarketBeat
American Century Companies Inc. Invests $570,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 6.9%What's Next? - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Franklin Resources Inc. - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at Jefferies Financial Group - MarketBeat
ADAR1 Capital Management LLC Acquires 19,061 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands - Bluefield Daily Telegraph
Attention Long-Term Shareholders of Axsome Therapeutics, - GlobeNewswire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Atika Capital Management LLC - MarketBeat
Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? - Yahoo Finance
Axsome (AXSM) Reports Positive Phase 3 Results for ADHD Treatmen - GuruFocus
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy - Yahoo Finance
Wellington Management Group LLP Has $56.96 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Investor Alert: Class Action Lawsuits Against General Motors, DocGo, Estée Lauder, and Axsome Therapeutics Survive Motions to Dismiss — Johnson Fistel, PLLP Encourages Shareholders to Contact the Firm - GlobeNewswire
403,026 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Purchased by Norges Bank - MarketBeat
AAN 2025: Axsome Therapeutics’ treatment for Alzheimer’s agitation shows promise - Yahoo
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to C - GuruFocus
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics - Bluefield Daily Telegraph
ALERT: Grabar Law Office Investigates Claims on Behalf of - GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - The Manila Times
Axsome Earnings Alert: CNS Drug Leader Sets Q1 2025 Results Date - Stock Titan
Jefferies Initiates Coverage of Axsome Therapeutics (BMV:AXSM) with Buy Recommendation - Nasdaq
Schroder Investment Management Group Sells 34,158 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Vanguard Group Inc. - MarketBeat
Jefferies Initiates Coverage of Axsome Therapeutics (LSE:0HKF) with Buy Recommendation - Nasdaq
Smoking Cessation and Nicotine Addiction Pipeline Analysis - openPR.com
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):